Table of Contents
MUMBAI and BALTIMORE, Md. — Pharma major Lupin announced the launch of tetrabenazine tablets, 12.5 mg and 25 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Tetrabenazine Tablets, 12.5 mg and 25 mg are the generic equivalent of Valeant Pharmaceuticals North America, LLC’s Xenazine tablets. It is indicated for the treatment of chorea associated with Huntington’s disease.